Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday

Orchestra BioMed (NASDAQ:OBIO) is expected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.9190 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Orchestra BioMed (NASDAQ:OBIO) last announced its earnings results on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.64. The firm had revenue of $30.92 million during the quarter, compared to analyst estimates of $0.93 million. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orchestra BioMed Stock Up 3.8%

NASDAQ OBIO traded up $0.15 on Monday, reaching $4.12. The company had a trading volume of 28,637 shares, compared to its average volume of 200,396. The firm has a market capitalization of $246.71 million, a price-to-earnings ratio of -3.64 and a beta of 0.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.43 and a current ratio of 6.45. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The company’s fifty day moving average is $4.34 and its 200-day moving average is $4.25.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on OBIO shares. Weiss Ratings lowered shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. Barclays upped their target price on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Finally, Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Orchestra BioMed has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

Insider Buying and Selling

In other Orchestra BioMed news, insider David P. Hochman purchased 10,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $4.29 per share, with a total value of $42,900.00. Following the transaction, the insider directly owned 1,086,467 shares of the company’s stock, valued at $4,660,943.43. This represents a 0.93% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Orchestra BioMed

Institutional investors and hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $118,000. Bank of America Corp DE raised its holdings in shares of Orchestra BioMed by 42.0% in the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock valued at $95,000 after purchasing an additional 7,036 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $76,000. Tower Research Capital LLC TRC raised its holdings in shares of Orchestra BioMed by 1,137.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 27,922 shares of the company’s stock valued at $75,000 after purchasing an additional 25,666 shares during the period. Finally, Cresset Asset Management LLC bought a new stake in shares of Orchestra BioMed in the 3rd quarter valued at about $74,000. 53.20% of the stock is owned by institutional investors.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.